title: Intralesional injection versus mouth rinse of triamcinolone acetonide in oral lichen planus: a randomized controlled study.
abstract: OBJECTIVE
  To compare the efficacy, relapse, and adverse effects between intralesional injection and mouth rinse of triamcinolone acetonide (TA) in patients with oral lichen planus (OLP).
  
  
  METHODS
  A randomized controlled study.
  
  
  METHODS
  College medical center.
  
  
  METHODS
  Forty consecutive patients, who had been diagnosed with OLP, were recruited. Participants were randomly divided into 2 groups using intralesional injection or mouth rinse of TA. The severity of pain and burning sensation on a 10-cm visual analog scale (VAS) and the Oral Health Impact Profile-14 (OHIP-14) were assessed at weeks 0, 1, 2, 3, 4, and 6. The signs of OLP were quantified using a special scoring system for OLP. The rate of relapse and the adverse effects were compared between both groups.
  
  
  RESULTS
  The VAS scores for pain and burning mouth sensation and objective scoring for OLP were significantly improved at 1, 2, 3, 4, and 6 weeks in both groups. The changes in the VAS for burning mouth sensation, OHIP-14, and objective scoring for OLP were similar between both groups. The change in the VAS for pain from baseline to week 1 in the intralesional injection group was significantly higher than in the mouth rinse group. The rate of adverse effects was significantly higher in the mouth rinse group than in the intralesional injection group (44.4% vs 5.0%).
  
  
  CONCLUSIONS
  The efficacies of both treatments were similar. The rate of adverse effects was significantly lower for intralesional injection of TA than mouth rinse of TA.
authors: Department of Otolaryngology-Head and Neck Surgery, Kyung Hee University School of Medicine, Seoul, Korea.
authors: Young Chan
authors: YC
authors: Lee
authors: Seung Youp
authors: SY
authors: Shin
authors: Sung Wan
authors: SW
authors: Kim
authors: Young Gyu
authors: YG
authors: Eun
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D017676:Lichen Planus, Oral / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009067:Mouthwashes; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D000893:Anti-Inflammatory Agents; D009067:Mouthwashes; D014222:Triamcinolone Acetonide